Market cap 128 Million, 4 clinical trials in progr
Post# of 72447
Posted On: 01/13/2016 10:35:26 PM
Market cap 128 Million, 4 clinical trials in progress. This is an unbelievably absurd valuation. Troubled GALE, with its scary cancer immunotherapy vaccine in development, and allegations of financial misdealings etc., has a market cap of 136 Million. They don't have the back-up drugs in a different field -- antibiotic (Brilacidin), psoriasis (Prurisol), and oral mucositis (Brilacidin-OM).
So basically, CTIX is valued at less than a company with one pipeline in a very difficult and unproven field. We KNOW that Kevetrin has shown efficacy, even with dose and dosing schedule not optimized, we KNOW that Brilacidin is effective. Wouldn't you think that just on the basis of Kevetrin and Brilacidin the so-called "efficient market" would put us at double the market cap of GALE, at the very least?
So basically, CTIX is valued at less than a company with one pipeline in a very difficult and unproven field. We KNOW that Kevetrin has shown efficacy, even with dose and dosing schedule not optimized, we KNOW that Brilacidin is effective. Wouldn't you think that just on the basis of Kevetrin and Brilacidin the so-called "efficient market" would put us at double the market cap of GALE, at the very least?
(0)
(0)